Nanostructured Lipid Carriers Loaded with Dexamethasone Prevent Inflammatory Responses in Primary Non-Parenchymal Liver Cells

Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liv...

Descripción completa

Detalles Bibliográficos
Autores: Medina-Montano, Carolina, Rivero Berti, Ignacio, Gambaro, Rocío Celeste, Limeres, María José, Svensson, Malin, Padula, Gisel, Chain, Cecilia Yamil, Cisneros, José Sebastián, Castro, Guillermo Raúl, Grabbe, Stephan, Bros, Matthias, Gehring, Stephan, Islan, Germán Abel, Cacicedo, Maximiliano Luis
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Argentina
Institución:Universidad Nacional de La Plata
Repositorio:SEDICI (UNLP)
Idioma:inglés
OAI Identifier:oai:sedici.unlp.edu.ar:10915/154307
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/154307
Access Level:acceso abierto
Palabra clave:Ciencias Exactas
Farmacia
glucocorticoids
lipid nanoparticles
liver inflammation
liver immunology
autoimmune hepatitis
dexamethasone
drug-controlled release
Descripción
Sumario:Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.

Similares en LA Referencia